WW INTERNATIONAL INC (WW)
NASDAQHealth CarePersonal Products & ServicesSnapshot 2026-09-04
$18.02+1.75%
Close 2026-09-04 · 1-day change
NASDAQHealth CarePersonal Products & ServicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
WW plans to cut its term loan by $40 million. Revenue is expected near $628 million in 2026. The company is expanding clinical services. These steps could help WW recover.
WW is losing money and revenue is shrinking. The CEO just resigned. These problems may get worse and hurt the business.
The market expects about 6% revenue decline next year. Our fair value is near $64.65, reflecting this weak outlook.
Breaks if: term loan reduction falls short of $40 million by end 2026
WW plans to utilize up to $40 million to prepay and reduce the principal amount of its outstanding term loan.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on growth in clinical and behavioral subscribers. The current thesis state is intact, supported by recent strong financial performance despite management volatility.
The market seems to price in a cheap valuation compared to peers, with a notable expectations gap. However, there is fragility in execution quality, which suggests that the market is not fully accounting for potential risks.
Fundamentals are expected to remain stable in the near term, as management is on track with key priorities like subscriber growth and margin maintenance. However, the recent drop in company momentum could signal challenges ahead.
The long-term thesis hinges on management's ability to maintain guidance and navigate potential economic headwinds, such as a weakening jobs report. Additionally, performance of sector peers like XWEL will be crucial for sustaining momentum.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. The company plans to prepay and reduce a term loan by $40 million. It also aims to grow its clinical and behavioral subscriber base.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: CEO position remains vacant or unstable past mid-2026
Breaks if: revenue falls below $620 million in FY26
Over the next 1 to 3 years, WW's performance will depend on effective management execution and external economic factors. Not investment advice.